Accelerating Clinical Development of Off-the-Shelf CD7 CAR-T

Wugen, Inc. has commenced patient enrollment in the global Phase 2 trial (T-RRex study, NCT06514794) of WU-CART-007 (active ingredient: soficabtagene geleucel), an allogeneic CD7-targeted Chimeric Antigen Receptor T-cell (CAR-T) therapy currently in development. This Phase 2 trial focuses on demonstrating efficacy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The strategy aims to overcome the manufacturing bottlenecks and risks of contamination associated with conventional autologous CAR-T therapies by utilizing an 'off-the-shelf' technology based on donor cells. The Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) validates the clinical potential of this pipeline.

Unique CRISPR-Based Gene Editing Technology

WU-CART-007 incorporates CRISPR/Cas9 gene editing technology to address fraticide (CAR-T cell fratricide) and Graft-versus-Host Disease (GvHD), which are challenges in CAR-T cell therapy. To prevent self-destruction, a common issue with CD7-targeted therapies, the CD7 gene is deleted. Simultaneously, the T-cell receptor alpha constant (TRAC) gene is knocked out to prevent the T cells from attacking the patient's body. This dual gene editing approach is designed to ensure high safety and long-term efficacy in patients with high-risk leukemia. The market will be closely watching to see if the long-term safety data of this precise editing platform is demonstrated in clinical trials.

Clinical Design Aiming for Complete Eradication of Minimal Residual Disease

The Phase 2 trial will enroll a total of 125 patients, divided into two cohorts: patients with relapsed/refractory disease and patients in complete remission with minimal residual disease (MRD). The primary endpoint is composite complete remission rate (CRc) and MRD negativity rate, allowing for a comprehensive evaluation of treatment efficacy. Achieving MRD negativity is a key indicator for significantly reducing the risk of leukemia relapse, and success could expand the use of the therapy to include patients with early relapse, a population with significant unmet needs. The data accumulated by the expected clinical completion date of December 2028 will serve as a critical basis for Wugen's future Biologics License Application (BLA).

High Unmet Need in a Rapidly Growing Hematological Cancer Market

The global market for T-ALL and T-LBL therapies is estimated at approximately $330 million in 2025 and is projected to reach $2.1 billion by 2035, with a potential peak of $5.4 billion by 2035. With limited alternatives to conventional chemotherapy and hematopoietic stem cell transplantation (HSCT), innovative new therapies are highly valued for T-cell malignancies. In particular, the discontinuation of development of bbT369, a CD7 pipeline from competitor 2seventy bio, after its acquisition by Regeneron, has increased Wugen's opportunity to establish a dominant market position. If Wugen successfully commercializes the first allogeneic CD7 CAR-T therapy, it could secure an irreplaceable position and generate substantial commercial benefits.

Series C Financing and Financial Stability

Wugen, a privately held company, completed a Series C equity financing round of $115 million in August 2025, led by Fidelity. This financing brings the company's total funding to over $400 million, providing a strong financial buffer to support the costs of the global Phase 2 trial. In the current challenging global biotech investment environment, securing a large investment from a major institutional investor reflects the market's high regard for Wugen's technology and pipeline. This solid financial structure and clinical progress will provide a foundation for a successful initial public offering (IPO) or licensing agreement with a multinational pharmaceutical company, maximizing valuation.